The findings from a study published in CANCER, a peer-reviewed journal of the American Cancer Society, shows that pediatric neuroblastoma patients are at elevated risk for long-term psychological impairment.
In addition, those who experience such impairment as they get older tend to require special education services and to not go on to college.
In the United States, neuroblastoma—a childhood cancer of nerve cells—is diagnosed at a median age of 17.3 months. Treatment advances in recent years have prolonged survival for many affected children, but their young age at diagnosis and the specific therapies they receive can make them vulnerable to health problems as their central nervous system develops.
To assess the long-term psychological effects of neuroblastoma and its treatment, Nina Kadan-Lottick, MD, MSPH, of Yale University School of Medicine and her colleagues studied 859 children who had been diagnosed with neuroblastoma at least five years earlier and were under 18 years old. Their median age at diagnosis was 0.8 years, and they were followed for a median of 13.3 years. These 859 neuroblastoma survivors were compared with 872 siblings of childhood cancer survivors.
Compared with siblings, neuroblastoma survivors had an increased prevalence of impairment in the domains of anxiety/depression (19% versus 14%), headstrong behavior (19% versus 13%), attention deficits (21% versus 13%), peer conflict/social withdrawal (26% versus 17%), and antisocial behavior (16% versus 12%).
Common treatments—vincristine, cisplatin, and retinoic acid—were not associated with impairment, but survivors who developed chronic health conditions as a result of their cancer treatment were at higher risk for developing worse outcomes.
Specifically, developing pulmonary disease was linked with an increased risk of impairment in all five domains, and developing endocrine disease and peripheral neuropathy were each linked with impairment in three domains. In addition, survivors who experienced psychological impairment tended to require special education services and to not go on to college.
Psychological and educational outcomes “These findings are novel because this is the first large study that could look at how neuroblastoma patients are doing in terms of psychological and educational outcomes. Before recent advances in treatment, this survivor population was much smaller and we were not able to analyze these sorts of long-term outcomes,” Kadan-Lottick noted.
“The goal is not simply to get our patients to be cancer-free but also to optimize their mental, emotional, and social functioning as they move into adolescence and adulthood. Our hope is that these findings will help inform strategies for early screening and intervention to identify those survivors at highest risk for developing psychological and educational impairment later on in life.”
June is National Cancer Survivors month.
Last Editorial Review: June 13, 2018
Featured Image: Real fluorescence microscopic view of human neuroblastoma cells. Courtesy: © 2010 – 2018 Fotolia. Used with permission. Photo 1.0: Nina Kadan-Lottick, MD Associate Professor of Pediatrics (Hematology / Oncology); Medical Director, HEROS Program. Courtesy: © 2010 – 2018 Yale School of Medicine. Used with permission.
Copyright © 2010 – 2018 Sunvalley Communication, LLC. All rights reserved. Republication or redistribution of Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of Sunvalley Communication. Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco’Zine, Oncozine and The Onco’Zine Brief are registered trademarks and trademarks of Sunvalley Communication around the world.